Newbury Pharmaceuticals Full Year 2024 Earnings kr0.64 loss per share - Simply Wall St
| NEWBRY Stock | 3.44 0.08 2.38% |
About 55% of Newbury Pharmaceuticals' investors are presently thinking to get in. The analysis of current outlook of investing in Newbury Pharmaceuticals AB suggests that some traders are interested regarding Newbury Pharmaceuticals' prospects. The current market sentiment, together with Newbury Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Newbury Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Newbury |
Newbury Pharmaceuticals Full Year 2024 Earnings kr0.64 loss per share Simply Wall St
Read at news.google.com
 |
Newbury Pharmaceuticals Fundamental Analysis
We analyze Newbury Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Newbury Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Newbury Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Newbury Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Newbury Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Newbury Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Newbury Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Newbury Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Newbury Pharmaceuticals Related Equities
| CLBIO | Corline Biomedical | 9.12 | ||||
| LIDDS | Lidds AB | 0.00 | ||||
| SPRINT | Sprint Bioscience | 1.09 | ||||
| CANTA | Cantargia | 1.64 | ||||
| KLAR | Klaria Pharma | 6.25 |
Complementary Tools for Newbury Stock analysis
When running Newbury Pharmaceuticals' price analysis, check to measure Newbury Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newbury Pharmaceuticals is operating at the current time. Most of Newbury Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newbury Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newbury Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newbury Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |